Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on Oct 04, 2018 4:44pm
122 Views
Post# 28747702

RE:RE:RE:RE:RE:This company is now profitable

RE:RE:RE:RE:RE:This company is now profitableIt is only frustrating if you were planning to sell today at $11 or $12. If you were long, if you trust the product and TH's management, you would be planning to keep your share until at least Feb 2020 and forget the noise until then. :) There might me manipulation, but obviously there is no investor that believe in TH and in Trogarzo. Shorts are simply taking advantage of it. They just dont have to work very hard to benefit from the situation. At the end, they are smart right now, but by keeping our shares we can say that longs are smart to. At least for those that believes SP will increase, slowly but surely.
Dwizell wrote: SPCEO1 - (10/4/2018 3:23:30 PM)
RE:RE:RE:This company is now profitable
palinc2000 wrote:
Dwizell wrote: I realy think everything is perfect. Increase in sales on egrifta , new formulation that will help raise the sales even more ( And decrease the cogs) .

The lunch of trogarzo is very good the sales progess very well, Europe is on the line and without too much cost ahead ... insurances coverage going week and we even made a profit !

But the stock is still totaly manipulate with the help of the thief working at rbc. Even with today’s great results and perspectives we are below the price we were before his malicious report and +\_ 35% from recent hights. We can’t barely  keep the post approval level ...

I am very happy with everything happening with th but totaly frustrated with the behavior of the stock price !


The notion that shorts are involved is probably accurate
The notion that RBC is somewhat involved in shorting or working with the shorts is pure nonsense
 


I beleive most of the shorts are related to the convert but there is some evidence that some are shorting THERF in an attempt to make a trading profit. Whatever case they had, it pretty much just got blown up. While RBC is not likely involved, I would not rule it out entirely. The report from RBC was so strange and out of consensus yet written by a smart guy, that it does raise a legitimate question of whether or not they might be supporting a client who is short. RBC today raised their price target to C$12 from C$11 and maintained a "Hold" rating on TH. Given the roughly 35% upside in the stock based on their own price target, that would seem to justify a :"Buy" rating. That the analyst did not raise his rating with that upside only raises suspicions. That the analyst did not raise his sales and EPS forecasts more is also dubious. He is a smart guy so his willingness to write up such a dubious report in the first place and his unwillingness to correct his errors now (including the math error noted earlier) means you can't fully rule out the short issue. 


So we have our respond .. he is the leader of the guild of theives .... 

is RBC itself involved ?  This has to be determined .....

So furstrating ...



Bullboard Posts